TCRT-PGEN Fundamental & Technical Discussion Board - One would think Boyle had/has conversations with AZN - TCRT-PGEN Fundamental & Technical Discussion Board - InvestorVillage


TCRT-PGEN Fundamental & Technical Discussion Board
This is a semi-private group. You are free to browse messages, but you must be a member of this group to post messages. Join This Group

Group: TCRT-PGEN Fundamental & Technical Discussion Board   /  Message Board  /  Read Message

 
 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  31461 of 32367  at  11/29/2022 7:56:38 PM  by

dachmeister4u

The following message was updated on 11/29/2022 8:14:41 PM.

 In response to msg 31453 by  2abetteryear
view thread

Re: One would think Boyle had/has conversations with AZN

From the Neogene website, their abstract presenting what needs to be done, the four bullet points below:
Copy/paste link:
https://www.neogene.com/staging/wp-content/uploads/2022/04/Keystone-2022-TGFBR2-KO-

TP53-R175H-TCR-poster-final-edit.pdf
>> TGFBR2 KO TCR-edited T cells can be efficiently
generated using multiplexed CRISPR-Cas9 engineering.
TGF-β signaling is almost completely disrupted
suggesting that TGFBR2 KO is very efficient.
TGFBR2 KO T cells are resistant to TGF-β-mediated
immunosuppression as shown by enhanced serial
killing, long-term proliferation and cytokine production.
Our next goal is to assess the pre-clinical safety and
potency of TP53 R175H TCR KI TGFBR2 KO T cell
products for subsequent clinical application. <<

NEOGENE is the firm that the NCI is also in CRADA for TCR-T, but using CRSPR transcription. They have a ways to go, including pre-clinical work in potency and safety (with CRSPR having a reputation for unintended, random changes to the human genome!). I am sure that Dr. Drew knows about their CRADA since DREW and the NCI talk frequently. Then again, remember Dr. Drew's slide and talk about SB -- simplicity, economic. Assuming that neoantigen targeting IS THE NCI's answer to solid cancers, I suggest the bar will be set high by Alaunos by the time Neogene/AZN is in clinical trials.

Interesting to read that PACT sold their out of their $50million South San Francisco lab. They thought they would be taking in tumor/blood samples, then sending back infusion bags all over the country. And Helen said SB/TCR-T will be bedside therapy in her 1Q21 cc! Did you see the writing on the wall, PACT? Poof.


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 13  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
31463 Re: One would think Boyle had/has conversations with AZN clsm 1 11/29/2022 8:44:08 PM




Financial Market Data provided by
.
Loading...